New Trial Medication for Pulmonary Arterial Hypertension

Trial Objective

The new investigational drug Ralinepag is designed to help the body receive prostacyclin known to widened blood vessels and relax artery walls, and potentially improve blood flow in adults with Pulmonary Arterial Hypertension (PAH). The ADVANCE OUTCOMES study is evaluating the effects of adding Ralinepag, to patients’ current PAH therapies. Once screened, participants will have 16 weeks to find their optimal dose before continuing to treatment.

New Trial Medication for Pulmonary Arterial Hypertension

Participants will have the option to continue in an extension study of Ralinepag (ADVANCE-extension) if they are eligible. The extension study will look at the effect of Ralinepag over a longer period of time.

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, contact Jennifer Underwood at 303.398.1518 or complete the form below.

Who Can Participate

Adults between 18 and 75 who have been diagnosed with Pulmonary Arterial Hypertension.


Estimated Time Commitment

Up to 42 months

The first four weeks will be spent screening participants. This will be followed by 16 weeks to find the optimal dosage for participants, after which treatment will start and patients will check in every 12 weeks until the end of the study, which is individual to each participant. After treatment there will be a final follow up after 30 days. There will be both clinic visits and telephone calls throughout the trial.

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

United Therapeutics

Age

18-75


Gender

Any Gender

Principal Investigators

Co-Investigators


Request More Information

*
*
*
*